Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Peter Kies Biography and Net Worth

CFO of Inovio Pharmaceuticals

Peter Kies is the chief financial officer at Inovio Pharmaceuticals, a role he has held since 2002.

Prior to Inovio, he spent 16 years acquiring experience in functional and strategic management for biotech and high-tech companies spanning the spectrum of corporate growth, ranging from IPO to profitability.

Kies held the role of CFO for both Genetronics Biomedical Corp. and Newgen Results Corporation. Before that, he worked as the controller for Cytel Corporation and as an auditor for Ernst & Young LLP.

He earned his B.S. in business administration at United States International University (now Alliant International University) in San Diego.

What is Peter Kies' net worth?: The estimated net worth of Peter Kies is at least $4,647.94 as of June 9th, 2021. Mr. Kies owns 1,142 shares of Inovio Pharmaceuticals stock worth more than $4,648 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Kies may own. Additionally, Mr. Kies receives a salary of $810,200.00 as CFO at Inovio Pharmaceuticals. Learn More about Peter Kies' net worth.
How old is Peter Kies?: Mr. Kies is currently 61 years old. There are 3 older executives and no younger executives at Inovio Pharmaceuticals. Learn More on Peter Kies' age.
What is Peter Kies' salary?: As the CFO of Inovio Pharmaceuticals, Inc., Mr. Kies earns $810,200.00 per year. The highest earning executive at Inovio Pharmaceuticals is Dr. Jacqueline E. Shea Ph.D., CEO, President & Director, who commands a salary of $1,130,000.00 per year. Learn More on Peter Kies' salary.
How do I contact Peter Kies?: The corporate mailing address for Mr. Kies and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at (267) 440-4200 and via email at [email protected]. Learn More on Peter Kies' contact information.
Has Peter Kies been buying or selling shares of Inovio Pharmaceuticals?: Peter Kies has not been actively trading shares of Inovio Pharmaceuticals in the last ninety days. Most recently, Peter Kies sold 234 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $1,441.44, for a transaction totalling $337,296.96. Following the completion of the sale, the chief financial officer now directly owns 1,142 shares of the company's stock, valued at $1,646,124.48. Learn More on Peter Kies' trading history.
Who are Inovio Pharmaceuticals' active insiders?: Inovio Pharmaceuticals' insider roster includes Simon Benito (Director), Laurent Humeau (Insider), Peter Kies (CFO), Jong Kim (CEO), Jacqueline Shea (COO), David Weiner (Director), and Lota Zoth (Director). Learn More on Inovio Pharmaceuticals' active insiders.

Peter Kies Insider Trading History at Inovio Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	234	$1,441.44	$337,296.96	1,142
6/3/2021	Sell	69	$1,156.32	$79,786.08	1,047
4/21/2021	Sell	69	$1,226.88	$84,654.72	1,116
1/15/2021	Sell	208	$1,442.88	$300,119.04	1,036
12/15/2020	Sell	138	$1,539.36	$212,431.68	889
7/15/2020	Sell	243	$3,592.80	$873,050.40	1,071
6/30/2020	Sell	243	$3,816.00	$927,288.00	828
11/29/2018	Sell	69	$760.32	$52,462.08	500
7/10/2018	Sell	243	$639.36	$155,364.48	674
10/9/2014	Buy	27	$1,454.40	$39,268.80

Peter Kies Buying and Selling Activity at Inovio Pharmaceuticals

Inovio Pharmaceuticals Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Today's Range

Now: $4.07

$4.04

$4.22

50 Day Range

MA: $5.50

$3.97

$6.82

2 Week Range

Now: $4.07

$3.85

$14.75

Volume

294,158 shs

Average Volume

383,765 shs

Market Capitalization

$106.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Nvidia is Pivoting to Solve Big Tech’s $1 Trillion Problem

From Weiss Ratings | Ad